These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37244259)

  • 1. Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity.
    Yan C; Zheng L; Jiang S; Yang H; Guo J; Jiang LY; Li T; Zhang H; Bai Y; Lou Y; Zhang Q; Liang T; Schamel W; Wang H; Yang W; Wang G; Zhu ZJ; Song BL; Xu C
    Cancer Cell; 2023 Jul; 41(7):1276-1293.e11. PubMed ID: 37244259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesterol atlas of tumor microenvironment provides route to improved CAR-T therapy.
    Chaves-Filho AB; Schulze A
    Cancer Cell; 2023 Jul; 41(7):1204-1206. PubMed ID: 37244258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LXR-dependent and -independent effects of oxysterols on immunity and tumor growth.
    Traversari C; Sozzani S; Steffensen KR; Russo V
    Eur J Immunol; 2014 Jul; 44(7):1896-903. PubMed ID: 24777958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy.
    Chen X; Yang S; Li S; Qu Y; Wang HY; Liu J; Dunn ZS; Cinay GE; MacMullan MA; Hu F; Zhang X; Wang P
    Mol Ther Oncolytics; 2021 Jun; 21():144-157. PubMed ID: 33981830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
    Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
    PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity.
    Alizadeh D; Wong RA; Gholamin S; Maker M; Aftabizadeh M; Yang X; Pecoraro JR; Jeppson JD; Wang D; Aguilar B; Starr R; Larmonier CB; Larmonier N; Chen MH; Wu X; Ribas A; Badie B; Forman SJ; Brown CE
    Cancer Discov; 2021 Sep; 11(9):2248-2265. PubMed ID: 33837065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.
    Zhang PF; Wang C; Zhang L; Li Q
    Immunotherapy; 2022 Apr; 14(6):459-473. PubMed ID: 35232284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
    Du X; Darcy PK; Wiede F; Tiganis T
    Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased 27-hydroxycholesterol production during luteolysis may mediate the progressive decline in progesterone secretion.
    Xu Y; Hutchison SM; Hernández-Ledezma JJ; Bogan RL
    Mol Hum Reprod; 2018 Jan; 24(1):2-13. PubMed ID: 29177442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
    Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
    Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cells deficient in cholesterol biosynthesis promote tumor immune evasion.
    Chen Y; Xu Y; Zhao H; Zhou Y; Zhang J; Lei J; Wu L; Zhou M; Wang J; Yang S; Zhang X; Yan G; Li Y
    Cancer Lett; 2023 Jun; 564():216208. PubMed ID: 37150500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
    Johnson A; Townsend M; O'Neill K
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
    Tang L; Zhang Y; Hu Y; Mei H
    Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.